Canada Approves Moderna's mRNA RSV Vaccine for Seniors

Health Canada has authorized Moderna's mRESVIA for adults 60 and older, marking the country's first mRNA-based RSV vaccination.

Moderna's mRESVIA vaccine is set to be available in early 2025, providing a new option for RSV prevention in older adults.
The vaccine is the first RSV shot in Canada to utilize mRNA technology, which could offer higher efficacy than traditional vaccines.
Health Canada has also approved protein-based RSV vaccines from GSK and Pfizer for similar age groups.
The National Advisory Committee on Immunization recommends RSV vaccination for adults 75+ and those 60+ in long-term care.
RSV is a leading cause of pneumonia in toddlers and older adults, with outbreaks typically occurring from late fall to early spring.